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Abstract
Introduction:  The  risk  of  systemic  bupivacaine  toxicity  is  a  persistent  problem,  which  makes
its pharmacokinetic  study  fundamental  for  regional  anesthesia  safety.  There  is  little  evidence
of its  influence  on  plasma  peak  at  different  concentrations.  The  present  study  compares  two
bupivacaine  concentrations  to  establish  how  the  concentration  affects  this  drug  plasma  peak
in axillary  brachial  plexus  block.  Postoperative  latency  and  analgesia  were  also  compared.
Methods:  30  patients  were  randomized.  In  the  0.25%  Group,  0.25%  bupivacaine  (10  mL)  was
injected per  nerve.  In  the  0.5%  Group,  0.5%  bupivacaine  (5  mL)  was  injected  per  nerve.  Periph-
eral blood  samples  were  collected  during  the  first  2  h  after  the  blockade.  For  sample  analyses,
high performance  liquid  chromatography  mass  spectrometry  was  used.
Results:  Plasma  peak  occurred  45  min  after  the  blockade,  with  no  difference  between  groups  at
the assessed  time-points.  Plasma  peak  was  933.97  ±  328.03  ng.mL−1 (mean  ±  SD)  in  0.25%  Group
and 1022.79  ±  253.81  ng.mL−1 in  0.5%  Group  (p  =  0.414).  Latency  was  lower  in  0.5%  Group  than
in 0.25%  Group  (10.67  ±  3.71  ×  17.33  min  ±  5.30,  respectively,  p  =  0.004).  No  patient  had  pain
within the  first  4  h  after  the  blockade.
Conclusion:  For  axillary  brachial  plexus  block,  there  was  no  difference  in  bupivacaine  plasma
peak despite  the  use  of  different  concentrations  with  the  same  local  anesthetic  mass.  The
concentration  inversely  influenced  latency.
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Efeitos  farmacocinéticos  e  clínicos  de  duas  concentrac¸ões de  bupivacaína
no  bloqueio  do  plexo  braquial  via  axilar
Resumo
Introduc¸ão:  O  risco  de  intoxicac¸ão  sistêmica  pelo  uso  da  bupivacaína  é  um  problema  persis-
tentee torna  seu  estudo  farmacocinético  fundamental  para  a  seguranc¸a da  anestesia  regional.
São escassas  as  evidências  sobre  a  influência  de  diferentes  concentrac¸ões  no  pico  plasmático
desse fármaco.  O  presente  estudo  compara  duas  concentrac¸ões  de  bupivacaína  para  estabele-
cer como  a  concentrac¸ão  afeta  o  pico  plasmático  desse  fármaco  no  bloqueio  do  plexo  braquial
via axilar.  Também  se  compararam  latência  e  analgesia  pós-operatória.
Métodos:  Foram  randomizados  30  pacientes.  No  Grupo  0,25%,  injetaram-se  10  mL  de  bupi-
vacaína 0,25%  por  nervo.  No  Grupo  0,5%,  injetaram-se  5  mL  de  bupivacaína  0,5%  por  nervo.
Amostras de  sangue  periférico  foram  colhidas  durante  as  duas  primeiras  horas  após  o  bloqueio.
Para análise  das  amostras,  usou-se  a  cromatografia  líquida  de  alta  frequência  acoplada  ao
espectrômetro  de  massas.
Resultados:  O  pico  plasmático  ocorreu  45  minutos  após  o  bloqueio,  sem  diferenc¸a  entre  os
grupos nos  tempos  avaliados.  O  pico  plasmático  (média  ±  DP)  foi  933,97  ±  328,03  ng.mL−1 no
Grupo 0,25%  e  1.022,79  ±  253,81  ng.mL−1 no  Grupo  0,5%  (p  =  0,414).  O  Grupo  0,5%  apresentou
menor latência  com  relac¸ão  ao  Grupo  0,25%  (10,67  ±  3,71  ×  17,33  min  ±  5,30;  respectivamente;
p =  0,004).  Nenhum  paciente  apresentou  dor  nas  primeiras  quatro  horas  após  o  bloqueio.
Conclusão:  Para  o  bloqueio  do  plexo  braquial  via  axilar,  não  foi  detectada  diferenc¸a no  pico
plasmático  de  bupivacaína  apesar  do  uso  de  diferentes  concentrac¸ões,  com  a  mesma  massa  de
anestésico  local.  A  concentrac¸ão  influenciou  inversamente  a  latência.
© 2017  Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Sociedade  Brasileira  de  Anestesiologia.
Este e´ um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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gists,  body  mass  index  (BMI)  less  than  35  kg  m−2, and  a  signedntroduction
he  success  of  regional  anesthesia  (RA)  is  directly  related
o  the  evolution  of  knowledge  and  the  development  of
ocal  anesthetics  (LA).  Despite  efforts  to  increase  its  safety,
 persistent  problem  in  clinical  practice  is  local  anes-
hetic  systemic  toxicity  (LAST).1,2 The  rapid  increase  in  LA
lasma  levels  leads  to  devastating  neurological  and  cardiac
omplications;  LA  systemic  toxicity  accounts  for  one-third
f  deaths  or  brain  damage  during  regional  anesthesia.3,4
egarding  RA  type,  peripheral  nerve  block  may  require  a
reater  LA  volume,  with  a  higher  risk  of  LAST  compared  to
pidural  block.1,5,6
The  increased  use  of  ultrasound  in  clinical  practice  has
educed  the  occurrence  of  complications  related  to  periph-
ral  block,  mainly  due  to  the  reduction  of  inadvertent
ascular  puncture.7,8 Moreover,  in  order  to  improve  the
afety  of  regional  anesthesia,  anesthesia  societies  around
he  world  recommend  using  the  minimum  dose  required  and
tipulate  the  maximum  LA  dose  to  be  used  in  peripheral
locks.9 However,  there  is  no  consensus  among  the  differ-
nt  societies  about  the  maximum  recommended  dose  of  LA,
hich  reveals  a  gap  in  understanding  the  pharmacokinetics
f  these  drugs.9 Furthermore,  there  are  several  factors  that
ay  influence  LA  plasma  peak  such  as  the  infusion  site  vas-
ularization  and  the  tissue  binding  ability.9Surprisingly,  data  on  the  effect  of  different  LA  con-
entrations  on  plasma  levels  are  scarce  and  conflicting
o  far.  However,  understanding  the  pharmacokinetics
w
i
hf  these  chemical  compounds  is  essential  to  prevent
omplications.10--12
This  study  was  performed  to  evaluate  this  relationship,
articularly  regarding  axillary  brachial  plexus  block.  Thus,
he  present  study  provides  an  analysis  of  the  pharmacoki-
etic  profiles  of  two  bupivacaine  concentrations  obtained
fter  axillary  brachial  plexus  block.  Despite  the  different
oncentrations  used,  the  total  mass  of  local  anesthetic  was
aintained  to  evaluate  the  effect  of  these  different  concen-
rations  on  this  drug  plasma  peak.  As  a  secondary  objective,
atency  and  postoperative  analgesia  were  evaluated  in  both
roups.
aterial and method
 prospective  and  randomized  clinical  trial  was  performed
t  the  operating  room  of  the  Hand  and  Upper  Limb  Surgery
epartment  at  a  quaternary  University  Hospital.  The  anes-
hetic  procedures  were  initiated  in  January  2014,  after
pproval  by  the  Ethics  and  Institutional  Research  Committee
pproval  number  288,461.  Inclusion  criteria  were:  candi-
ates  for  elective  distal  forearm  and  hand  surgery,  with
rachial  plexus  block  indication  for  anesthesia  and  analge-
ia,  aged  between  18  and  65  years,  with  physical  status  (ASA
 or  II)  according  to  the  American  Society  of  Anesthesiolo-ritten  informed  consent.  Exclusion  criteria  were:  cognitive
mpairment,  infection  at  the  puncture  site,  coagulopathy,
istory  of  bupivacaine  allergy.
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Shapiro--Wilk  test  was  used  to  verify  if  the  analyzedPharmacokinetic  and  clinical  effects  of  two  bupivacaine  con
Clinical  methodology
After  meeting  the  inclusion  criteria,  patients  were  random-
ized  into  groups  to  receive  either  0.25%  bupivacaine  or
0.5%  bupivacaine,  according  to  computer-generated  random
numbers,  which  were  considered  as  blocks  of  ten  cases.
The  0.25%  bupivacaine  concentration  was  used  because
it  is  the  lowest  effective  concentration  for  axillary  brachial
plexus  block.13 The  0.5%  concentration  was  used  because  it
is  the  highest  bupivacaine  concentration  used  in  our  service.
For  greater  accuracy  of  information,  the  patient  received
explanation  to  the  differences  between  tactile  and  painful
sensation.  Routine  monitoring  for  surgical  procedure  with
electrocardioscopy,  sphygmomanometer,  and  pulse  oxime-
try  was  performed.  Venous  access  was  obtained  in  the  upper
limb  contralateral  to  the  surgical  procedure,  exclusively  for
blood  sample  collection.
The  axillary  brachial  plexus  block  guided  by  ultrasound
(S  Series,  Fujifilm  Sonosite,  Seattle,  USA)  was  performed  by
a  single  experienced  anesthetist,  with  the  patient  in  the
horizontal  dorsal  decubitus  position,  aiming  at  standardiz-
ing  the  blockade  time,  defined  as  the  interval  between  the
needle  insertion  and  the  end  of  LA  injection.  Thus,  this  time
would  not  influence  the  latency  of  groups.  Skin  asepsis  was
made  with  a  chlorhexidine-alcohol  solution.  After  brachial
plexus  nerve  visualization,  LA  was  injected  into  each  nerve
identified  in  this  pathway  --  namely,  radial,  ulnar,  medial,
and  musculocutaneous.  For  the  0.25%  Group,  10  mL  of  0.25%
bupivacaine  (Cristália  Produtos  Químicos,  São  Paulo,  Brazil)
were  injected  into  each  nerve,  totaling  40  mL  per  patient.
For  the  0.5%  Group,  5  mL  of  0.5%  bupivacaine  (Cristália  Pro-
dutos  Químicos,  São  Paulo,  Brazil)  were  injected  into  each
nerve,  totaling  20  mL  per  patient.
An  anesthesiologist,  who  was  not  present  during  the
injection  and  was  blinded  to  the  concentration  and  volume
of  anesthetics  used,  evaluated  the  nerve  blocks  according
to  motor  function,  thermal  sensitivity,  and  pain  sensitivity.
In  order  to  evaluate  motor  function,  the  modified  Bro-
mage  scale  was  used  (Table  1).14,15 The  assessed  muscles
were:  finger  flexors  (median  nerve),  finger  extensors  (radial
nerve),  first  finger  adductor  (ulnar  nerve),  and  biceps  (mus-
culocutaneous  nerve).
Thermal  sensation  assessment  was  made  with  gauze  and
alcohol,  testing  the  sensitivity  of  the  dermatomes  inner-
vated  by  the  ulnar,  median,  radial,  and  musculocutaneous
nerves.
The  assessment  of  pain  sensation  at  the  upper  limb  was
performed  with  the  pinprick  test  (23G  needle),  testing  the
sensitivity  of  the  ulnar,  median,  radial,  and  musculocuta-
neous  dermatomes  nerves.
This  assessment  happened  every  five  minutes  up  to  30  min
after  the  blockade.  In  this  period,  if  surgical  anesthesia  had
not  been  achieved,  a  supplemental  injection  of  ultrasound-
guided  bupivacaine  was  performed,  distal  to  the  axilla,  and
the  patient  was  excluded  from  the  protocol.
Surgical  anesthesia  was  defined  as  a  motor  scale  less  than
or  equal  to  Bromage  two,  with  no  sensation  of  cold  and  pin-
prick  in  the  assessed  dermatomes  and  also  if  there  was  no
need  for  anesthetic  supplementation  during  the  procedure.
The  end  of  the  LA  solution  injection  was  considered
as  time  zero  (T0)  to  evaluate  the  blockade  success  rate.
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atency  was  defined  as  the  time  interval  between  T0  and
he  time  at  which  the  surgical  anesthesia  was  achieved.
During  surgical  procedure,  patients  received  midazolam
0.05  mg.kg−1) for  sedation.  After  surgical  procedure,  the
atient  was  admitted  to  the  post-anesthesia  care  unit,
here  he  remained  for  four  hours  in  order  to  assess  the  need
or  analgesic  supplementation.
aboratory  methodology
enous  blood  samples  were  collected  before  the  blockade,
very  15  minutes  (min)  during  the  first  hour  and  every  30  min
n  the  second  hour  after  the  blockade,  through  an  exclu-
ive  cannula.  Initially,  5  mL  were  collected  and  scavenged
o  avoid  any  contamination  from  the  previous  collection.
ubsequently,  another  5  mL  were  collected  and  stored  in
wo  EDTA  tubes.  EDTA  tubes  were  centrifuged  at  3500  ×  g
or  10  min  to  obtain  blood  plasma.  The  obtained  plasma  was
tored  in  cryogenic  tubes  in  a  freezer  at  a  temperature  of
80 ◦C  until  analysis.
A  High  Performance  Liquid  Chromatography  --  HPLC  (Shi-
adzu,  Kyoto,  Japan)  was  used  for  the  analysis,  coupled  to
he  mass  spectrometer  (Bruker  Amazon,  USA)  with  electro-
pray  ionization  source16 and  sequential  mass  spectrometry
ystem  (MS/MS).
After  obtaining  the  precursor  ion,  a  fragment  from  the
recursor  ion  dissociation  was  obtained  by  the  collision-
nduced  dissociation  process.  HPLC--MS/MS  data  were
onitored  for  internal  standard  (tryptophan)  and  bupiva-
aine  standard.  Positive  mode  analyzes  were  performed
n  the  MS/MS  mode  with  selection  of  molecular  ions  at
89  m/z  ⇒  140.1  m/z,  bupivacaine.  The  methodology  was
alidated  in  accordance  with  the  Food  and  Drug  Adminis-
ration  international  recommendations.17
tatistical  analysis
he  aim  of  this  study  was  to  evaluate  the  difference  in  the
aximum  plasma  levels  achieved  after  ultrasound-guided
xillary  brachial  plexus  block  with  two  different  concentra-
ions  of  bupivacaine  and  maintenance  of  the  infused  mass.
o  calculate  the  sample  size  needed  to  reveal  this  differ-
nce,  the  following  assumptions  were  considered:  (1)  null
ypothesis:  H0:  P0  25  max  =  P0  5  max;  alternative  hypothe-
is  Ha:  P0  25  max  >  P0  5  max,  where  P0  25  max  =  peak  plasma
chieved  in  the  0.25%  Group  and  P  0.5%  =  peak  plasma
chieved  in  the  0.5%  Group;  (2)  test  for  comparison  of  two
ndependent  sample  means  with  a known  standard  deviation
Student’s  t-test);  (3)  significance  level  of  5%  (˛  =  0.05);  (4)
ample  power  of  80%  (1  −  ˇ  =  0.80).
Considering  the  difference  of  about  40%  reported  in  the
iterature  for  intramuscular  injection,  the  sample  size  was
alculated  as  14  patients  per  group.  Considering  a  loss  rate
f  approximately  10%  during  collection  and  analysis,  the
ample  number  was  increased  to  32  patients.  All  analyzes
ere  performed  using  SPSS  (v  18.0)  and  Minitab  (v  16).ata  were  normally  distributed.  For  quantitative  varia-
les  with  normal  distribution,  the  Student’s  t-test  was
sed.  ANOVA  was  used  to  assess  the  variance  between
118  L.H.  Ferraro  et  al.
Table  1  Motor  and  sensory  test.14,15
Motor  test  Local  sensitive  test
Median  Finger  flexion Thenar  eminence
Radial Wrist  extension  Back  of  the  hand
Ulnar Abduction  of  the  5th  finger  Hypothenar  eminence
Musculocutaneous  Elbow  flexion  Forearm  lateral  region
Score Definition
4  Full  muscle  strength  in  relevant  muscle  groups
3 Reduced  strength,  but  able  to  move  against  resistance
2 Ability  to  move  against  gravity,  but  not  against  resistance
1 Discrete  movements  (trembling)  of  muscle  groups
0 Lack  of  movement
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Table  2  Demographics  of  patients.
0.25%  Group  0.5%  Group  p
n  15  15
Age (years)  36.0  (10.3)  35.7  (12.1)  0.93a
BMI  (kg  m−2)  25.7  (3.9)  26.2  (3.2)  0.7a
Sex
M/F  10/5  11/4
ASA
I/II 7/8  6/9
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higher  concentration  drug,  the  surface  area  available  forModified Bromage Scale.14,15
uantitative  variables. The  level  of  significance  was  5%
˛  <  0.05)  and  the  tests  with  a  descriptive  level  below  5%
p  < 0.05)  were  considered  significant.18
esults
 total  of  35  patients  were  selected  for  the  study.  Three
atients  were  not  included  for  not  meeting  the  inclusion
riteria  while  32  patients  were  randomized.  There  was  no
ifficulty  in  visualizing  the  axillary  brachial  plexus  via  ultra-
ound.  Two  patients,  one  from  each  group,  were  excluded
rom  the  protocol  due  to  blockade  failure;  30  patients
ompleted  the  protocol  up  to  sample  analysis  (Fig.  1).  Demo-
raphic  data  of  patients  are  shown  in  Table  2.
Blockade  time  was  192  ±  28  s  for  the  0.5%  Group  and
04  ±  32  s for  the  0.25%  Group  (p  =  0.462);  it  did  not  influ-
nce  the  latency  time  measurement.  However,  the  blockade
atency  of  the  0.5%  Group  was  statistically  lower  than  that
f  the  0.25%  Group  (Table  3).  In  addition,  no  difference  was
een  in  the  duration  of  surgical  procedures  (Table  3).
In  all  patients  in  whom  surgical  blockade  was  achieved,
he  surgical  procedures  were  uneventful.  During  the  block-
de,  no  inadvertent  intravascular  puncture  was  observed,
hich  could  impair  the  outcome  evaluation.  In  addition,
o  mild  or  severe  symptoms  of  LA  systemic  toxicity  were
bserved  (e.g.,  tinnitus,  perioral  tingling,  or  seizures).
egarding  postoperative  analgesia,  no  patient  reported  pain
p  to  four  hours  after  the  blockade.  All  patients  were  dis-
harged  on  the  same  day  of  the  procedure  and  there  was  no
ase  of  hospital  readmission.
Regarding  the  pharmacokinetic  study,  the  used  doses  of
upivacaine,  in  mg.kg−1,  were  similar  between  groups  and
id  not  interfere  with  the  results  achieved  (0.25%  Group
-  1.33  ±  0.19;  0.5%  Group  --  1.32  ±  0.19,  p  =  0.826).  Plasma
oncentrations  of  bupivacaine  after  axillary  brachial  plexus
lock  for  0.5%  and  0.25%  groups  are  shown  in  Table  4  and
ig.  2.  There  was  no  difference  between  plasma  anesthetic
oncentrations  at  any  time.  The  peak  plasma  for  both  groups
ccurred  45  min  after  the  blockade.  The  mean  maximum
oncentration  of  bupivacaine  was  933.97  ±  328.03  ng.mL−1
or  0.25%  Group  and  1022.79  ±  253.81  ng.mL−1 for  0.5%
roup.
a
a
wBMI, Body Mass Index.
a Student’s t-test, age and BMI presented as mean (SD).
The  different  concentrations  of  LA  used  did  not  affect
ow  fast  the  peak  plasma  was  reached  (Table  4  and  Fig.  2).
iscussion
A  plasma  concentration  depends  on  the  dose  adminis-
ered,  rate  of  systemic  absorption,  tissue  distribution,  and
rug  clearance.  The  decrease  in  LA  systemic  absorption
ncreases  its  safety  margin  in  clinical  practice.  LA  dose  is  the
ariable  most  manipulated  by  the  physician  during  clinical
ractice.  The  doctor  can  set  the  total  dose  to  be  adminis-
ered  and  whether  the  drug  is  given  in  a  more  concentrated
r  more  diluted  solution.  The  present  study  aim  was  verify
he  relationship  between  the  LA  concentration  and  its  peak
lasma.  Despite  the  difference  in  bupivacaine  concentra-
ion  between  groups,  the  present  study  outcomes  showed
hat  the  maximum  plasma  level  achieved  was  similar.
These  results  are  similar  to  those  of  a  previous  study
hat  failed  to  find  a  difference  in  the  maximum  level
f  LA  in  epidural  anesthesia  when  the  mass  was  main-
ained  constant.12 Thus,  this  result  increases  the  evidence
hat  it  is  the  total  dose  of  LA  that  regulates  the  drug
harmacokinetics.19,20
One  possible  explanation  would  be  that  when  using  thebsorption  is  smaller,  which  would  result  in  a  systemic
bsorption  equal  to  that  of  the  lower  concentration  drug  but
ith  a larger  surface  area  available  for  absorption.  It  may
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Figure  1  Clinical  flow  chart  of  the  study.
Table  3  Blockade  latency  and  surgical  time  per  group.
Technique  variables  0.25%  Group
(n  =  15)
0.5%  Group
(n  =  15)
p
Latency  (min)  0.004
Mean (standard  deviation)  17.3  (5.3)  10.7  (3.7)
Median 20  10
Duration  of  surgery  (min)
Mean  (standard  deviation)  88.6  (49.8)  83.9  (44.9)  0.41
Median 70  70
Student’s t-test.
Table  4  Comparison  of  plasma  bupivacaine  concentration  at  each  time  point  after  blockade.
Time.min−1 Bupi  0.25%  (ng.mL−1)
Mean  (SD)a
95%  CIa Bupi  0.5%  (ng.mL−1)
Mean  (SD)a
95%  CIa p
15  447.07  (162.37)  364.91--529.24  525.22  (149.66)  449.49--600.96  0.181
30 791.76  (251.32)  664.58--918.95  826.59  (232.27)  709.05--944.14  0.696
45 933.97  (328.03)  767.97--1099.98  1022.79  (253.81)  894.35--1151.24  0.414
60 631.37  (214.45)  521.83--740.9  709.98  (191)  613.32--806.6  0.301
90 614.85  (307.71)  459.13--770.58  615.18  (196.33)  515.83--714.54  0.997
120 410.95  (117.09)  351.69--470.2  470.14  (122.8)  408--532.29  0.187
a ine.
2
f
b
p
iSD, standard deviation; CI, confidence interval; Bupi, bupivaca
Student’s t-test.
be  suggested  that  the  surface  area  available  for  absorption
plays  an  important  role  in  the  plasma  peak  of  LA,  neutralizes
the  effect  of  the  difference  in  concentrations.  This  find-
ing  is  demonstrated  by  the  same  peak  plasma  concentration
and  by  the  same  pattern  of  plasma  concentration  over  time
in  both  groups,  despite  different  concentrations.  In  addi-
tion,  a  possible  difference  in  osmolarity  between  solutions
could  result  in  different  peak  plasma  levels  between  groups.
The  osmolarity  of  the  solutions  used  in  this  study  were
l
s
e93  mOsmoL.L−1 for  0.25%  bupivacaine  and  239  mOsmoL.L−1
or  0.5%  bupivacaine.  However,  the  osmolarity  difference
etween  groups  did  not  influence  the  plasma  peak.
In  a  previous  study,  Cohen  et  al.  demonstrated  that  a
ortion  of  the  higher  concentration  solutions  could  precip-
tate  when  injected  into  a tissue  pH  >  6.9.  Solutions  with
ower  concentrations  did  not  show  this  precipitation.10 The
olutions  used  in  the  present  study  had  the  same  pH.  How-
ver,  one  limitation  of  the  study  was  not  to  assess  whether
120  L.H.  Ferraro  et  al.
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Aigure  2  Distribution  of  mean  and  standard  deviation  of  bu
fter blockade.
his  precipitation  also  occurred  with  bupivacaine  at  higher
oncentration  in  the  axillary  pathway,  which  would  decrease
he  drug  availability  for  absorption.
In addition,  another  interesting  result  of  the  present
tudy  was  that  blockade  latency  was  lower  for  the  0.5%
roup  than  for  the  0.25%  bupivacaine  Group.  A  possible
xplanation  for  this  result  is  that  when  the  surface  area
vailable  for  exchange  is  limited,  LA  concentration  becomes
he  main  determinant  of  the  latency  period.  A  previous  study
as  determined  that  the  minimum  LA  volume  required  to
nvolve  the  nerves  in  axillary  brachial  plexus  block  is  about
.5  mL.21 In  the  present  study,  the  lowest  infusion  volume
as  5  mL  per  nerve.  Therefore,  the  volume  injected  per
erve  was  greater  than  the  minimum  volume  required  to
nvolve  the  entire  nerve  structure  in  both  groups.  Thus,  the
olume  used  was  sufficient  to  encompass  the  entire  neu-
al  exchange  surface,  with  no  difference  between  groups
egarding  this  factor.  In  this  case,  the  concentration  prob-
bly  becomes  the  most  important  factor  related  to  the
ransmembrane  passing  through  rate  when  the  surface  area
s  the  same.  This  would  explain  the  shorter  latency  period
n  the  0.5%  bupivacaine  group.
Motor  and  sensory  blockade  duration  could  not  be  eval-
ated  due  to  the  outpatient  nature  of  the  service.  Despite
his  difference  in  blockade  latency,  postoperative  analgesia
p  to  four  hours  was  the  same  between  groups,  showing  that
he  use  of  different  concentrations  did  not  alter  analgesia
uring  this  period.
Regarding  LAST  symptoms,  a  previous  study  demon-
trated  that  following  intravenous  bupivacaine  infusion,
atients  had  mild  toxicity  symptoms  (i.e.,  mouth  tingling,
izziness,  and  tinnitus)  with  plasma  concentrations  ranging
rom  1000  to  2000  ng.mL−1.  Infusion  was  done  at  a rate
f  10  mg.min−1 up  to  a  maximum  dose  of  150  mg  or  until
he  first  symptoms  appeared.22 Although  the  plasma  peak
f  bupivacaine  seen  in  some  patients  in  the  present  study
lso  reached  values  between  1000  and  2000  ng.mL−1 in  both
roups,  this  effect  occurred  after  45  min  of  perineural  infu-
ion  and  no  patient  had  LAST  symptoms.  These  results  are
imilar  to  that  of  previous  studies  on  the  pharmacokine-
W
t
taine  plasma  concentration  per  group  at  different  time  points
ics  of  bupivacaine  during  axillary  brachial  plexus  block,23,24
hich  found  plasma  peak  levels  within  that  interval  without
ny  of  the  patients  showing  symptoms  of  LA  toxicity.23The
ate  at  which  the  maximum  plasma  level  is  reached  proba-
ly  alters  the  systemic  effects  of  toxicity.  In  addition,  the
ime  required  to  reach  the  plasma  peak  concentration  in  the
resent  study  was  similar  to  that  reported  by  other  authors
ho  described  the  pharmacokinetic  profile  of  bupivacaine
uring  axillary  brachial  plexus  block.  This  finding  emphasizes
hat  an  episode  of  LAST  is  more  likely  to  occur  during  the
rst  hour  after  the  blockade,  regardless  of  the  concentration
sed.  As  all  patients  were  sedated  during  the  surgical  proce-
ure,  any  awareness  of  mild  symptoms  of  LAST  was  limited.
onclusion
he  aim  of  this  study  was  to  increase  knowledge  about  the
A  pharmacokinetics  to  increase  the  safety  of  RA.  This  study
hows  that  there  is  no  difference  in  peak  plasma  levels  of
upivacaine,  despite  the  use  of  different  concentrations
nd  volumes,  since  the  LA  mass  was  constant.  However,
oncentration  played  an  important  role  in  determining  this
lockade  latency  period,  inversely  influencing  the  latency
eriod.
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